INTRODUCTION {#rjx053s4}
============

Over 2500 continuous left ventricular assist devices (LVAD) devices were implanted in United States in 2014 and over 20 000 have been implanted worldwide to date \[[@rjx053C1]\]. With the increasing prevalence of ventricular assist devices, non-cardiac surgeries for this patient population are becoming a more frequently encountered clinical scenario. Patients with adenocarcinoma of the head of the pancreas who undergo surgery and adjuvant therapy have a 5-year survival of approximately 20% \[[@rjx053C2]\]. Patients with adenocarcinoma of the pancreas who are not surgical candidates and receive only chemotherapy with or without radiation have a median survival of \~7--10 months \[[@rjx053C3]\]. Clearly, surgery plays a critical role in the potential survival of patients with adenocarcinoma of the pancreas. Herein, we present a patient with an LVAD who was subsequently diagnosed with adenocarcinoma of the head of the pancreas. After careful consideration of the overall prognosis in this patient with this complex clinical presentation, we elected to perform a pancreaticoduodenectomy.

CASE REPORT {#rjx053s5}
===========

A 66-year-old male with New York Heart Association (NYHA) stage IV heart failure, severe aortic stenosis, severe aortic insufficiency and porcelain aorta underwent implantation of a HeartMate II  LVAD as destination therapy by the Cardiac Transplant and Mechanical Heart Service at our institution on October 26, 2013. Nine months later, routine laboratory follow up done July 20, 2014 revealed an elevated total bilirubin of 6.3 (0.2--1.1 mg/dL). Abdominal ultrasound showed cholelithiasis and intra- and extra-hepatic biliary ductal dilation. Abdominal computed tomography (CT) was not able to delineate the distal common bile duct or pancreas head area due to LVAD artifact (Figs. [1](#rjx053F1){ref-type="fig"}a and b). At this point, the patient\'s anticoagulation was reversed and the patient underwent endoscopic retrograde cholangiopancreatography (ERCP). Fluoroscopy for the ERCP was limited by the LVAD, however, a tight distal common bile duct stricture of about 2 cm in length was noted (Fig. [2](#rjx053F2){ref-type="fig"}). ERCP was followed immediately by  endoscopic ultrasound (EUS) that showed a 2.8 cm pancreatic head mass (Fig. [3](#rjx053F3){ref-type="fig"}). On EUS, the mass was not abutting the portal vein, superior mesenteric vein, superior mesenteric artery or celiac artery. Also, there was no significant lymphadenopathy per EUS. Fine needle aspiration of the pancreatic head mass was consistent with adenocarcinoma. Rest of the work-up included a chest-CT which was negative for metastatic disease, CA19-9 was 27 (0--37 U/mL). The case was discussed at our multidisciplinary liver and pancreas tumor board and after several care conferences with the family and involved providers, the decision was made to proceed with a pancreaticoduodenectomy on August 14, 2014. Figure 1:(**a**) Cross sectional imaging as a pre-operative study to define the pancreatic anatomy is limited by the LVAD artifact. (**b**) Computed tomography scout film shows the location of the LVAD and LVAD driveline in the chest and abdomen.Figure 2:ERCP images illustrate the common bile duct with distal stricture, partially obstructed by the LVAD.Figure 3:Endoscopic ultrasound images of the adenocarcinoma of the head of the pancreas.

Initial diagnostic laparoscopy was negative for metastatic disease, and confirmed expected adhesions to the LVAD Gortex pouch that is fashioned from the diaphragm (Fig. [4](#rjx053F4){ref-type="fig"}). After confirming the absence of metastatic disease, we then proceeded with a standard pancreaticoduodenectomy. We also had to do a small segment side bite resection of the portal vein with primary repair due to suspected involvement. He tolerated the procedure well and without any blood transfusions, estimated blood loss was 200 mL. He was extubated at the end of the case and was transferred to the Cardiac Intensive Care Unit for further care. A drain left around the hepatico and pancreatico jejunal anastomosis was removed on post-operative Day \#3 after checking the amylase level per our institutional protocol. By post-operative Day \#8 he was tolerating a regular soft diet and having regular bowel function. He did not have any infectious or bleeding complications post-operatively. He stayed in the hospital until post-operative Day \#17 mainly for close management of his overall fluid status and optimizing anticoagulation per the Mechanical Heart team. His final pathology showed a 3.0 cm, well differentiated tumor, without lympho-vascular invasion, with peri-neural invasion, with three lymph nodes positive by direct extension out of 17 total, surgical margins clear of cancer, Stage IIB, T3N1M0. Figure 4:A pouch made of Gortex and secured to the inferior face of the diaphragm houses the LVAD and sits over the mid and upper quadrants of the abdomen.

Approximately 6 weeks after surgery, he was started on adjuvant chemotherapy with single agent Gemcitabine. He completed total of 6 months of Gemcitabine without major side effects.

At the time this report was drafted, the patient was 30 months out from surgery with no evidence of recurrent disease.

Discussion {#rjx053s6}
==========

Pancreatic cancer pre-operative imaging {#rjx053s6a}
---------------------------------------

Due to LVAD streaking artifact on CT, pre-operative good quality imaging of the pancreas was only possible with endoscopic ultrasound.

Surgical challenges {#rjx053s6b}
-------------------

### Incision (presence of the LVAD driveline---Fig. [3](#rjx053F3){ref-type="fig"}) {#rjx053s6b_1}

Our incision had to be altered from our standard midline supra-umbilical incision in order to avoid the driveline (Fig. [5](#rjx053F5){ref-type="fig"}). As depicted in Figs [1](#rjx053F1){ref-type="fig"}a and b, the LVAD pump occupies a significant amount of the left abdominal wall from the costal margin to the umbilicus. The driveline also loops across the abdomen and exits in the left abdominal wall. The surgeon needs to be aware of these factors and be flexible with the location of the incision. Figure 5:Dotted line shows the subcutaneous location of the driveline (LVAD power cord). A typical midline incision or subcostal incision was not feasible due to the driveline trajectory.

### Retraction and exposure {#rjx053s6b_2}

Components of the inflow and outflow cannulas of the LVAD are made of pliable materials, therefore continuous intra-operative flow monitoring by a mechanical heart engineer is required for these cases.

### Linear flow (HeartMate CF) and identification of vascular structures {#rjx053s6b_3}

Identification of the superior mesenteric artery, celiac artery, hepatic artery, gastroduodenal artery or any arterial anatomic variants (i.e. replace right hepatic artery) is key to the operation. In patients with previous LVAD the lack of arterial pulsatile flow makes identification of these structures by palpation or Doppler not possible. Intra-operative ultrasound plays a bigger role for identification of vascular structures.

### Post-operative anticoagulation {#rjx053s6b_4}

LVAD patients are routinely kept anticoagulated with a target INR (international normalized ratio) between 1.8 and 2.5. In our case, the INR was corrected and the patient was kept on a heparin drip until two hours prior to surgery. Full dose intra-venous heparin drip was started on post-operative Day 2 and Coumadin was started on post-operative Day 3.

CONCLUSION {#rjx053s7}
==========

Close collaboration with the LVAD team is key to the successful care of these patients. Based on our limited experience, currently at our institution previous history of LVAD is not an absolute contraindication for major abdominal oncologic surgery.
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